⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146456 | 1.00 | — | — | |
| SCHEMBL407700 | 1.00 | — | — | |
| Water SCHEMBL10833358 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL19611556 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL5584535 | 0.95 | — | — | |
| Cyclopropane SCHEMBL17100916 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL4000615 | 0.74 | NPSR1 (0.32) | — | |
| SCHEMBL9971058 | 0.70 | — | — | |
| SCHEMBL22442 | 0.70 | — | — | |
| SCHEMBL14416084 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1751 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540136-B2 | Pyrrolopyridine derivative and use thereof | ST PHARM CO., LTD. (KR) | 2026-02-03 | — | — | US | claimed |
| US-12337274-B2 | Methods for absorption and desorption of carbon dioxide | SAUDI ARABIAN OIL COMPANY (SA) | 2025-06-24 | — | — | US | claimed |
| US-20240001291-A1 | METHODS FOR ABSORPTION AND DESORPTION OF CARBON DIOXIDE | SAUDI ARABIAN OIL COMPANY (SA) | 2024-01-04 | — | — | US | claimed |
| US-20230373994-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2023-11-23 | — | — | US | claimed |
| EP-4201405-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | ST Pharm Co., Ltd. (KR) | 2023-06-28 | — | — | EP | claimed |
| WO-2022039551-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | 에스티팜 주식회사 | 2022-02-24 | — | — | WO | claimed |
| EP-4747254-A1 | <SUP2/>? <SUB2/>?2B?5-HTSEROTONIN RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4695231-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042731-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | CORTEVA AGRISCIENCE LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12540136-B2 | Pyrrolopyridine derivative and use thereof | ST PHARM CO., LTD. (KR) | 2026-02-03 | — | — | US | disclosed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250276978-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2025-09-04 | — | — | US | disclosed |
| EP-0699185-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-5846986-A | Therapeutic phenoxyalkylazoles and phenoxyalkylazines | SANOFI (FR) | 1998-12-08 | — | — | US | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
| US-5721261-A | TREATING PICORNAVIRUS INFECTIONS | SANOFI PHARMACEUTICALS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5552420-A | TREATING PICORNAVIRAL INFECTIONS | STERLING WINTHROP INC. (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1995031452-A1 | THERAPEUTIC PHENOXYALKYLAZOLES AND PHENOXYALKYLAZINES | SANOFI WINTHROP, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |